ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
NCT01001377
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1010
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Cetuximab
DRUG:
Panitumumab
Sponsor
Amgen